BioPharmSignal logoBioPharmSignal

Biotech News

Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio (ZURA)Zura BioEarnings

TibuSHIELD topline data in hidradenitis suppurativa (HS) remains on track for Q4 2026; enrollment completed with 247 participants randomized, exceeding target TibuSURE topline data in systemic sclerosis (SSc) remains on track for H1 2027; enrollment completed with 91 participants randomized,

Related news

SNGXSOLIGENIX2026-11-06 12:30 EST

Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results

AVTXAvalo Therapeutics2026-11-05 12:00 EST

Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

CABACabaletta Bio2026-11-05 12:30 EST

Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

SABSSAB Biotherapeutics2026-10-29 12:30 EST

SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET

KNSAKiniksa2026-10-27 11:30 EST

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

MLTXMoonLake Immunotherapeutics2026-11-04 12:00 EST

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update

ATYRaTyr Pharma2026-11-05 21:01 EST

aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update

REGNRegeneron Pharmaceuticals2026-10-30 10:30 EST

Regeneron Reports Third Quarter 2026 Financial and Operating Results

View all latest news

Zura Bio

Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...

Recent company news

ZURAZura Bio2026-10-27 22:00 EST

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZURAZura Bio2026-10-27 11:30 EST

Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates

ZURAZura Bio2026-08-31 20:30 EST

Zura Bio to Participate in the Cantor Global Healthcare Conference

ZURAZura Bio2026-08-21 23:57 EST

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZURAZura Bio2026-08-11 11:30 EST

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

Stock data

Close
3.72 USD
Market cap
389.01M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States